Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Frank C, Albers"'
Autor:
Alberto Papi, Bradley E. Chipps, Richard Beasley, Reynold A. Panettieri, Elliot Israel, Mark Cooper, Lynn Dunsire, Allison Jeynes-Ellis, Robert Rees, Frank C. Albers, Christy Cappelletti
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
What is this summary about? This summary describes the results of a clinical study called MANDALA that was published in the New England Journal of Medicine in 2022. In the MANDALA study, researchers looked at a new asthma rescue inhaler that contains
Externí odkaz:
https://doaj.org/article/0ab12cc7d5194d5cbd16b7128e28d089
Autor:
Catherine Lemiere, Camille Taillé, Jason Kihyuk Lee, Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric S. Bradford, Steven W. Yancey, Mark C. Liu
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Severe asthma is associated with a broad range of phenotypes and clinical characteristics. This analysis assessed whether select baseline patient characteristics could prognosticate mepolizumab efficacy in severe eosinophilic asth
Externí odkaz:
https://doaj.org/article/30952c4dc0464539b159797ac01e55b9
Autor:
Mark C. Liu, Bradley Chipps, Xavier Munoz, Gilles Devouassoux, Miguel Bergna, Steven G. Smith, Robert G. Price, Dmitry V. Galkin, Jay Azmi, Dalal Mouneimne, Frank C. Albers, Kenneth R. Chapman
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patient
Externí odkaz:
https://doaj.org/article/b4e2e90b44bf489cab4a132a23dc52f2
Autor:
Mi-Kyeong Kim, Hae-Sim Park, Choon-Sik Park, Soung-Jun Min, Frank C. Albers, Steven W. Yancey, Bhabita Mayer, Namhee Kwon
Publikováno v:
The Korean Journal of Internal Medicine, Vol 36, Iss 2, Pp 362-370 (2021)
Background/Aims The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Met
Externí odkaz:
https://doaj.org/article/231f886fb296415ea39634ca177fb176
Autor:
Alberto Papi, Bradley E Chipps, Frank C Albers, Laurence Reilly, Eva Johnsson, Christy Cappelletti
Publikováno v:
BMJ Open Respiratory Research, Vol 8, Iss 1 (2021)
Introduction Uncontrolled asthma is associated with substantial morbidity. While fast-acting bronchodilators provide quick relief from asthma symptoms, their use as rescue fails to address the underlying inflammation. Combining a short-acting beta2-a
Externí odkaz:
https://doaj.org/article/67c25686f3124adabef5fee2b47d8950
Autor:
Frank C. Albers, Alberto Papi, Camille Taillé, Daniel J. Bratton, Eric S. Bradford, Steven W. Yancey, Namhee Kwon
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI). Methods This was a post hoc individual patient-leve
Externí odkaz:
https://doaj.org/article/debcfbe2e06343d8aade0172271b5331
Autor:
Charlene M. Prazma, Elisabeth H. Bel, Robert G. Price, Eric S. Bradford, Frank C. Albers, Steven W. Yancey
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-4 (2019)
Abstract Background An inverse relationship between oral corticosteroid (OCS) dose and peripheral blood eosinophil (PBE) count is widely recognized in patients with severe eosinophilic asthma; however, there are limited data available to quantify thi
Externí odkaz:
https://doaj.org/article/aeca2cd394c54e4d94ecc2068191b9b7
Autor:
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey
Publikováno v:
ERJ Open Research, Vol 6, Iss 3 (2020)
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticoster
Externí odkaz:
https://doaj.org/article/d061689a1e2545f094dab881d225191f
Autor:
Namhee Kwon, Emilio Pizzichini, Aruna T. Bansal, Frank C. Albers, Neil Barnes, John H. Rile, Aline Lima-matos, Eduardo Viera ponte, Alvaro A. Cruz
Publikováno v:
World Allergy Organization Journal, Vol 13, Iss 5, Pp - (2020)
Background: Improved understanding of the normal range of blood eosinophil counts (BEC) and conditions that influence them in non-asthmatic individuals should allow more accurate estimation of the threshold at which eosinophilic disease should be con
Externí odkaz:
https://doaj.org/article/cdcdb95ce3e7483194e8e9a6f0c25c7e
Autor:
REYNOLD A PANETTIERI, BRADLEY E CHIPPS, RICHARD BEASLEY, ELLIOT ISRAEL, FRANK C ALBERS, JOHN BELL, CHRISTY CAPPELLETTI, ANNA DANILEWICZ, LYNN DUNSIRE, ILEEN GILBERT, PER GUSTAFSON, ROBERT REES, FRANK TRUDO, MARK WEINBERG, ALBERTO PAPI
Publikováno v:
Chest. 162:A52-A56
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34c25e33058eac50e2fe000f9fceb824
https://doi.org/10.1016/j.chest.2022.08.030
https://doi.org/10.1016/j.chest.2022.08.030